FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985964605> ?p ?o ?g. }

• W1985964605 endingPage "151" @default.
• W1985964605 startingPage "145" @default.
• W1985964605 abstract "This is a phase II, single-center, single-arm study of patients with resectable adenocarcinoma of the pancreas who were treated with adjuvant interferon-based chemoradiation followed by gemcitabine. The primary end point was 2-year overall survival, with secondary endpoints being 2-year disease-free survival, and the frequency of grade 3 or 4 toxicity.From April 2002 to September 2005, 53 patients with adenocarcinoma of the pancreas underwent curative resection at a single institution, and subsequently received interferon- and gemcitabine-based adjuvant therapy consisting of external-beam irradiation at a dose of 5040 cGy (25 fractions per 5 weeks) and simultaneous 3-drug chemotherapy consisting of (1) continuous infusion 5-fluorouracil (175 mg/m2); (2) weekly intravenous bolus cisplatin (25 mg/m2); and (3) interferon-alpha (3 million units subcutaneously 3 times per week) during the 6 weeks of radiation. This was followed by two 4-week courses of weekly intravenous infusion of gemcitabine (1000 mg/m2, 3 of 4 weeks).Median follow-up is 38 months. Seventy-seven percent of patients had node-positive disease. Sixteen patients (30%) failed to complete adjuvant therapy, due to disease progression (7 patients), toxicity (7 patients), and consent withdrawal (2 patients). No patients completed planned therapy without dose modification. Median overall survival was 25 months (confidence interval [CI] = 21.5-48.5 months). Actuarial overall survival for the 1-, 2- and 3-year periods were 75% (CI = 61-85%), 56% (CI = 41-69%), and 41% (26-55%), respectively.This phase II trial demonstrated increased patient survival compared with historical controls, and equivalent survival compared with the regimen combining interferon-alpha with 5-fluorouracil-based chemoradiation. Despite these encouraging results, significant concerns regarding dose- and treatment-limiting toxicities remain." @default.
• W1985964605 created "2016-06-24" @default.
• W1985964605 creator A5023459185 @default.
• W1985964605 creator A5034354367 @default.
• W1985964605 creator A5040229780 @default.
• W1985964605 creator A5048989612 @default.
• W1985964605 creator A5050288292 @default.
• W1985964605 creator A5053434373 @default.
• W1985964605 creator A5060050760 @default.
• W1985964605 creator A5065596046 @default.
• W1985964605 creator A5074460989 @default.
• W1985964605 creator A5079031946 @default.
• W1985964605 creator A5090231642 @default.
• W1985964605 date "2008-08-01" @default.
• W1985964605 modified "2023-10-16" @default.
• W1985964605 title "Adjuvant Interferon-based Chemoradiation Followed By Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study" @default.
• W1985964605 cites W2000751577 @default.
• W1985964605 cites W2005660567 @default.
• W1985964605 cites W2010605589 @default.
• W1985964605 cites W2047318784 @default.
• W1985964605 cites W2075244358 @default.
• W1985964605 cites W2089166784 @default.
• W1985964605 cites W2091188319 @default.
• W1985964605 cites W2093616734 @default.
• W1985964605 cites W2111736523 @default.
• W1985964605 cites W2115812130 @default.
• W1985964605 cites W2129197203 @default.
• W1985964605 cites W2150881991 @default.
• W1985964605 cites W4241578751 @default.
• W1985964605 doi "https://doi.org/10.1097/sla.0b013e318181e4e9" @default.
• W1985964605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18650621" @default.
• W1985964605 hasPublicationYear "2008" @default.
• W1985964605 type Work @default.
• W1985964605 sameAs 1985964605 @default.
• W1985964605 citedByCount "54" @default.
• W1985964605 countsByYear W19859646052012 @default.
• W1985964605 countsByYear W19859646052014 @default.
• W1985964605 countsByYear W19859646052015 @default.
• W1985964605 countsByYear W19859646052016 @default.
• W1985964605 countsByYear W19859646052017 @default.
• W1985964605 countsByYear W19859646052018 @default.
• W1985964605 countsByYear W19859646052020 @default.
• W1985964605 countsByYear W19859646052021 @default.
• W1985964605 countsByYear W19859646052022 @default.
• W1985964605 countsByYear W19859646052023 @default.
• W1985964605 crossrefType "journal-article" @default.
• W1985964605 hasAuthorship W1985964605A5023459185 @default.
• W1985964605 hasAuthorship W1985964605A5034354367 @default.
• W1985964605 hasAuthorship W1985964605A5040229780 @default.
• W1985964605 hasAuthorship W1985964605A5048989612 @default.
• W1985964605 hasAuthorship W1985964605A5050288292 @default.
• W1985964605 hasAuthorship W1985964605A5053434373 @default.
• W1985964605 hasAuthorship W1985964605A5060050760 @default.
• W1985964605 hasAuthorship W1985964605A5065596046 @default.
• W1985964605 hasAuthorship W1985964605A5074460989 @default.
• W1985964605 hasAuthorship W1985964605A5079031946 @default.
• W1985964605 hasAuthorship W1985964605A5090231642 @default.
• W1985964605 hasConcept C121608353 @default.
• W1985964605 hasConcept C126322002 @default.
• W1985964605 hasConcept C141071460 @default.
• W1985964605 hasConcept C203092338 @default.
• W1985964605 hasConcept C2776694085 @default.
• W1985964605 hasConcept C2776737053 @default.
• W1985964605 hasConcept C2778764654 @default.
• W1985964605 hasConcept C2780258809 @default.
• W1985964605 hasConcept C2781182431 @default.
• W1985964605 hasConcept C31760486 @default.
• W1985964605 hasConcept C535046627 @default.
• W1985964605 hasConcept C71924100 @default.
• W1985964605 hasConcept C90924648 @default.
• W1985964605 hasConceptScore W1985964605C121608353 @default.
• W1985964605 hasConceptScore W1985964605C126322002 @default.
• W1985964605 hasConceptScore W1985964605C141071460 @default.
• W1985964605 hasConceptScore W1985964605C203092338 @default.
• W1985964605 hasConceptScore W1985964605C2776694085 @default.
• W1985964605 hasConceptScore W1985964605C2776737053 @default.
• W1985964605 hasConceptScore W1985964605C2778764654 @default.
• W1985964605 hasConceptScore W1985964605C2780258809 @default.
• W1985964605 hasConceptScore W1985964605C2781182431 @default.
• W1985964605 hasConceptScore W1985964605C31760486 @default.
• W1985964605 hasConceptScore W1985964605C535046627 @default.
• W1985964605 hasConceptScore W1985964605C71924100 @default.
• W1985964605 hasConceptScore W1985964605C90924648 @default.
• W1985964605 hasIssue "2" @default.
• W1985964605 hasLocation W19859646051 @default.
• W1985964605 hasLocation W19859646052 @default.
• W1985964605 hasOpenAccess W1985964605 @default.
• W1985964605 hasPrimaryLocation W19859646051 @default.
• W1985964605 hasRelatedWork W2067379301 @default.
• W1985964605 hasRelatedWork W2086275648 @default.
• W1985964605 hasRelatedWork W2100029565 @default.
• W1985964605 hasRelatedWork W2160509211 @default.
• W1985964605 hasRelatedWork W2167571882 @default.
• W1985964605 hasRelatedWork W2589786235 @default.
• W1985964605 hasRelatedWork W2599122764 @default.
• W1985964605 hasRelatedWork W3000087759 @default.
• W1985964605 hasRelatedWork W3011672858 @default.
• W1985964605 hasRelatedWork W3161613711 @default.

• next